Study Author, year | Timing of randomisation | ART | COH protocols | Total | Initiation of P | Dose & route of administration | No. | Early P cessation group | No. | Continuation group |
---|---|---|---|---|---|---|---|---|---|---|
Kohls, 2012 | Clinical pregnancy | IVF/ICSI | GnRH-anta | 220 | OR | vaginal P 200mg bid | 110 | week 5 | 110 | week 8 |
Kyrou, 2011 | Positive hCG test | IVF/ICSI | GnRH-anta | 200 | ET | vaginal P 200mg tid | 100 | the 16th day post-ET | 100 | week 7 |
Goudge, 2010 | COH | IVF | GnRH-a/GnRH-anta | 101 | ET/OR | IM P50mg qd | 53 | the 11th day post-ET | 48 | week 6 |
Aboulghar, 2008 | Clinical pregnancy | ICSI | GnRH-a | 257 | Unstated | IM or vaginal P | 125 | week 6-7 | 132 | week 9-10 |
Andersen, 2002 | Positive hCG test | IVF/ICSI | GnRH-a | 303 | ET | vaginal P 200mg tid | 150 | the 14th day post-ET | 153 | week 7 |
Prietl, 1992 | Positive hCG test | IVF | CC/hMG/GnRH-a | 120 | Unstated | PC500mg/EV10mg tiw | 65 | the 12th day post-ET | 55 | week 12 |